Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential TASOXIRI With Bevacizumab for Late-Line Metastatic Colorectal Cancer
NCT05806931Phase 2Recruiting
- Sponsor
- Rutgers University
- Start
- May 2023
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of trifluridine + tipiracil in colorectal cancer (CRC), sponsored by Rutgers University. Started May 2023; status: recruiting.
02
Drugs
trifluridine + tipiracil
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05806931.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05806931.